A Clinical Trial Evaluating a Total Disc Replacement in Patients with Cervical Disc Disease

	Prospectively registered
No longer recruiting	☐ Protocol
Overall study status	Statistical analysis plan
Completed	Results
Condition category	☐ Individual participant data
Last EditedCondition category07/06/2010Musculoskeletal Diseases	Record updated in last year
	Completed Condition category

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Scott Kitchell

Contact details

1200 Hilyard Eugene United States of America 97401

Additional identifiers

Protocol serial number

NUVA-CP-0904

Study information

Scientific Title

A Non-Randomised Controlled Clinical Trial Evaluating a Total Disc Replacement in Patients with Cervical Disc Disease

Study objectives

This study will be a non-randomized trial consisting of patients with single level (C3 to C7) symptomatic cervical disc disease who have not previously received fusion surgery at the same level, and have failed to improve with conservative treatment for at least 6 weeks prior to enrollment, or who present with progressive neurological symptoms or signs in the face of conservative treatment.

Ethics approval required

Old ethics approval format

Ethics approval(s)

The medical ethics committee of El Centro Medico Hospital del Prado approved on the 15th of April 2010 (ref: NUVA-CP-0904)

Study design

Non-randomized multicentre historically controlled

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Degenerative Disc Disease

Interventions

Cervical spinal reconstruction

Intervention Type

Other

Phase

Not Applicable

Primary outcome(s)

Individual patient success at 24 months, tested using Blackwelders method for testing non-inferiority with delta of 10%.

Success is defined as:

- 1. Improvement in the Neck Disability Index (NDI) by \geq 15 points at 24 months compared to Baseline
- 2. No device failures requiring revision, re-operation (including supplemental fixation), or removal from the patient
- 3. No device-related serious adverse event and
- 4. Maintenance or improvement of neurologic status (based on sensory, motor, and reflex assessment scores and observational gait analysis)

Key secondary outcome(s))

- 1. Range of Motion (ROM) defined as more than 3 degrees total flexion / extension. If the ROM is less than or equal to 3° the patient will be defined as having 'non-motion'
- 2. Fusion (defined as \leq 3° of ROM at the operative level, absence of radiolucent lines around \geq 50% of the implant, and no displacement or migration of the device (defined as > 3mm abnormal

movement measured from AP and lateral plain films)

- 3. SF-36 improvement of \geq 15% at 24 months compared to Baseline
- 4. Visual analog pain scale (VAS) improvement of \geq 20 mm at 24 months compared to Baseline
- 5. Disc height from the lateral radiograph showing maintenance or improvement from Baseline at 24 months

Completion date

31/12/2010

Eligibility

Key inclusion criteria

- 1. Age: 18-60 years of age (inclusive and skeletally mature)
- 2. A diagnosis of symptomatic cervical disc disease, defined as image-confirmed pathology: herniated disc, spondylosis, and/or loss of disc height. Spondylosis is defined as image-confirmed disc desiccation, loss of disc height, bridging osteophytes, and/or uncovertebral arthrosis. Loss of disc height is specified as a measurement of at least 25% less than an adjacent nonsymptomatic level, but with a minimum of 1mm height remaining
- 3. Functional neurological deficit (i.e., exhibits at least one sign associated with cervical level to be treated, including abnormal reflex, decreased motor strength, abnormal dermatome sensitivity, or pain in a dermatomal distribution);
- 4. Symptomatic level is C3-4, C4-5, C5-6 or C6-7 (one level)
- 5. Preoperative Neck Disability Index (NDI) ≥ 30 points (considered moderate disability; Vernon 1991);
- 6. Unresponsive to conservative treatment for \geq 6 weeks, and/or exhibits progressive symptoms and/or signs of nerve root and/or spinal cord compression in the face of conservative treatment
- 7. Not pregnant, nor interested in becoming pregnant within the follow-up period of the study
- 8. Willing and able to comply with the requirements defined in the protocol for the duration of the study
- 9. Signed and dated Informed Consent

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Upper age limit

60 years

Sex

All

Key exclusion criteria

- 1. Prior cervical fusion, prior laminectomy (prior cervical laminotomy that has not violated the facets need not be excluded), and/or prior cervical facetectomy at the operative level
- 2. Requiring surgical treatment that would leave the patient with a postoperative deficiency of the posterior elements
- 3. Signal changes in the cord on preoperative T2-weighted MRI and/or clinically significant myelopathy which would be described as gait disturbance, loss of manual dexterity, or bowel or bladder incontinence/retention.
- 4. Radiographic signs of significant instability at operative level (> 3mm translation, > 11° rotation different from adjacent level)
- 5. Bridging osteophytes or motion < 3°
- 6. Radiographic confirmation of significant facet joint disease or degeneration
- 7. Chronic neck or arm pain of unknown etiology
- 8. Cervical fracture, anatomic anomaly, or deformity (e.g. ankylosing spondylitis, scoliosis) at the levels to which the prosthesis will be attached
- 9. Severe spondylolisthesis (greater than grade 1)
- 10. Endocrine disorders or connective tissue diseases
- 11. Rheumatoid arthritis or other autoimmune disease
- 12. Progressive neuromuscular disease, e.g., muscular dystrophy, multiple sclerosis
- 13. Chronic steroid users
- 14. Taking any medications or drugs in doses that are known to potentially interfere with the bone metabolism or soft tissue healing, which may include (but is not limited to) the following: inhaled glucocorticoids for asthma, corticosteroids, thyroid hormones, blood thinners (heparin, warfarin), gonadotropin-releasing hormone agonists for prostate cancer treatment, contraceptive medroxyprogesterone, lithium for bi-polar disorder treatment, anticonvulsants, aluminum-containing antacids, tetracycline
- 15. Osteoporosis to a degree that spinal instrumentation would be contraindicated (DEXA T-score less than or equal to -2.5; DEXA necessary only if patient exhibits risk factors for low bone mass as quantified in DEXA screening questionnaire)
- 16. Diabetes mellitus requiring insulin management
- 17. Presence of metastases or active spinal tumor malignancy
- 18. Body Mass Index (BMI) > 40
- 19. Active local or systemic infection, including AIDS, hepatitis
- 20. Having been enrolled in another investigational device study within the last 90 days
- 21. Having had another cervical device implanted that would interfere with the surgical approach, study or control device, or follow-up evaluations
- 22. Demonstrates 3 or more signs of nonorganic behavior, such as Waddells signs
- 23. History of substance abuse
- 24. Involved in spinal litigation
- 25. Mentally incompetent
- 26. Incarcerated

Date of first enrolment

26/05/2010

Date of final enrolment

31/12/2010

Locations

Countries of recruitment

Mexico

Study participating centre 1200 Hilyard

Eugene United States of America 97401

Sponsor information

Organisation

Nuvasive Inc. (USA)

ROR

https://ror.org/036dqy506

Funder(s)

Funder type

Industry

Funder Name

Nuvasive Inc. (USA)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?

Participant information sheet Participant information sheet 11/11/2025 No